Duane Morris Class Action Review - 2023 - Report - Page 292
5. $5 billion – In Re National Prescription Opiate Litigation, Case No. 17-MD02804 (N.D. Ohio Feb. 25, 2022) (settlement agreement reached with Johnson
& Johnson, the consumer products and health company that manufactured
generic opioid medications, to resolve the vast majority of the opioid lawsuits filed
by state and local governmental entities).
6. $5 billion – In Re National Prescription Opiate Litigation, Case No. 17-MD02804 (N.D. Ohio Nov. 2, 2022) (settlement agreement reached with retail
pharmacy Walgreens to settle all opioid claims against it by participating states,
subdivisions and tribes).
7. $4.9 billion – In Re National Prescription Opiate Litigation, Case No. 17-MD02804 (N.D. Ohio Nov. 2, 2022) (settlement agreement reached with retail
pharmacy CVS Pharmacy to settle all opioid claims against it by participating
states, subdivisions and tribes).
8. $4.25 billion – In Re National Prescription Opiate Litigation, Case No. 17MD-02804 (N.D. Ohio Nov. 22, 2022) (settlement agreement reached with Teva
Pharmaceutical Industries to resolve thousands of lawsuits by U.S. state and
local governments over the marketing of opioid painkillers).
9. $3.1 billion – In Re National Prescription Opiate Litigation, No. 17-MD-02804
(N.D. Ohio Nov. 15, 2022) (settlement agreement reached with retail store WalMart to resolve all opioid lawsuits and potential lawsuits by state, local, and tribal
governments).
10. $2.37 billion – In Re National Prescription Opiate Litigation, Case No. 17MD-02804 (N.D. Ohio Nov. 22, 2022) (settlement agreement reached with
Abbvie Inc. to resolve thousands of lawsuits by U.S. state and local governments
over the marketing of opioid painkillers).
291
© Duane Morris LLP 2023
Duane Morris Class Action Review – 2023
